Navigation Links
Advance in Program for Development of Non-Intravenous Therapy for Hemophilia

Baxter AG and Jerini AG in Germany have announced progress in their collaborative research program to develop a non-intravenous therapy// for the treatment of hemophilia.

Extensive in vitro and in vivo analysis has identified several synthetic lead molecules with promising pharmacological properties.

"Using our proprietary technology platform, we continue to make important progress in our collaboration with Baxter, the leader in hemophilia therapy," said Jens Schneider-Mergener, Jerini AG's chief executive officer. "We are encouraged by the identification of these molecules and the evaluation of the potential to treat hemophilia using a non-intravenous therapy with molecules that can be synthetically produced."

Scientists from Baxter and Jerini used proprietary tailored screening and analysis methods to design molecules with the ability to promote the coagulation of blood. Following further analysis, several principal molecules that showed promising activity in mouse models of hemophilia were selected for further development.

Because blood-clotting proteins are large, relatively unstable molecules, current hemophilia therapies can only be administered intravenously, which is an invasive and technically demanding procedure. It is presently not possible to administer these molecules by non-intravenous routes because of poor distribution or rapid inactivation of the molecule in the body. Therefore, potential non-intravenous therapy must be able to reach its target site quickly and effectively without being inactivated in the process.

"We are very pleased by the progress to date in this collaboration with Jerini," said Friedrich Scheiflinger, PhD, senior director of discovery research and technical assessment for Baxter's BioScience business. "This partnership builds on Baxter's rich history of innovation in hemophilia therapy development and underscores our long-term commitment to improving therapies for people wi th hemophilia."

The collaboration between Baxter and Jerini was initiated in 2001 and expanded in 2004. Under the terms of the agreement, Jerini received an upfront payment, with the potential for milestone payments for achieving discovery, preclinical and clinical goals as well as royalties in the event of marketing approval.

About Hemophilia People with hemophilia do not produce adequate amounts of factor VIII or factor IX protein, which are necessary for blood to effectively clot. If untreated, patients with severe hemophilia have a greatly reduced life expectancy. According to the World Health Organization, more than 400,000 people in the world have hemophilia, corresponding to a prevalence of 15 to 20 in every 100,000 males born worldwide.

Baxter hemophilia research and development Baxter is a global leader in hemophilia therapy, with innovations that span 40 years. Through its own scientific expertise and strategic partnerships, Baxter is applying novel technologies that will pioneer the next generation of hemophilia therapies. Baxter's goal is to greatly enhance treatment convenience through therapies that require fewer injections and offer non-intravenous dosing alternatives.

About Jerini AG Jerini AG is a pharmaceutical company based in Berlin, Germany focusing on the discovery and development of peptide-based drugs. Having recognized the potential of peptides as natural starting molecules for drug discovery, the company has developed state-of-the-art technologies to identify and transform peptides into drugs. The company's lead product, Icatibant, is currently in Phase III clinical trials for the treatment of hereditary angioedema (HAE). It is estimated that between 1:10,000 and 1:50,000 people worldwide are affected with this disease. Based on its technology platform, Jerini has established several in-house development programs, which address indications within ophthalmology, oncology, and inflammatory t herapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries.

About Baxter Baxter AG is a subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning non-intravenous hemophilia therapy. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continuing clinical developments in identifying and developing suitable molecules; results demonstrating the safety and efficacy of the products; other risks inherent in development of early-stage therapies; and other risks identified in the company's most recent filing on Form 10-Q and other SEC filings, all of which are available on the company's web site. The company does not undertake to update its forward-looking statements.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Advanced STD programs required
3. Hope For Patients With Advanced Breast Cancer
4. Advances In Stem Cells Research
5. Breast Cancer Advance
6. Canadian Lung Cancer Study Lauded As Major Advance in Cancer Fight
7. Speedier Access To Advances In Breast Cancer Sought For Patients
8. HIV Vaccine Field Trials In Advanced Stage
9. Advance Funeral For AIDS-infected South African
10. New Screening Techniques to Lead Advances In Pain Therapy
11. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology: